nccrp1 Antibody

What is NCCRP1 and what is its cellular localization?

NCCRP1 was originally described as a transmembrane protein in fish immune cells, but more recent studies have definitively shown it is an intracellular protein. Immunocytochemistry studies demonstrate that human NCCRP1 is expressed intracellularly, contradicting initial predictions of it being a type II or type III membrane protein. Bioinformatic analyses using tools such as TMHMM, SignalP, and TargetP consistently predict the absence of transmembrane domains or signal peptides in NCCRP1 across all studied species, indicating cytoplasmic localization . When designing experiments with NCCRP1 antibodies, researchers should account for this intracellular localization rather than surface expression.

What are the closest protein relatives of NCCRP1?

The closest paralogs of NCCRP1 are the FBXO genes whose protein products function as components of E3 ubiquitin ligase complexes. Specifically, FBXO2, FBXO6, FBXO17, FBXO27, and FBXO44 share significant homology with NCCRP1. Human NCCRP1 shares 31-36% protein sequence identity with these five lectin-type FBXO proteins in the C-terminal 180 residues . When validating NCCRP1 antibodies, researchers should consider possible cross-reactivity with these related proteins and perform appropriate control experiments.

What is the tissue expression pattern of NCCRP1 in different species?

NCCRP1 expression varies across species, which has implications for experimental design and comparative studies:

This diverse expression pattern suggests different functional roles across species and tissues, requiring careful consideration when using NCCRP1 antibodies in comparative studies .

How should researchers validate NCCRP1 antibody specificity?

When validating NCCRP1 antibodies, Western blotting after SDS-PAGE separation is a recommended approach. Recombinant human NCCRP1 appears as a polypeptide of approximately 30 kDa . Researchers should run proper positive controls (recombinant protein) and negative controls (normal serum or isotype controls) alongside their samples. Mass spectrometry can provide further confirmation, as tryptic digestion of purified NCCRP1 yields a characteristic pattern of peptides covering approximately 75% of the sequence . For immunocytochemistry applications, siRNA knockdown controls are essential to confirm antibody specificity and avoid misinterpretation of results.

Are there species-specific considerations when selecting NCCRP1 antibodies?

Yes, significant structural differences exist between fish and mammalian NCCRP1 proteins. Mammalian sequences feature a proline-rich N-terminal domain of approximately 60 residues that is absent in fish sequences. Conversely, fish sequences contain unique insertions around positions 150 and 190 in the alignment . Additionally, the F-box domain is more clearly defined in mammalian sequences than in fish. These structural differences may affect epitope accessibility and antibody recognition, requiring careful selection of antibodies appropriate for the species under investigation.

What are the key structural features of NCCRP1?

NCCRP1 contains several notable structural features that influence antibody selection and experimental design:

• F-box-associated (FBA) domain and galactose-binding domain-like pattern in the C-terminal region

• A putative F-box domain in the N-terminal region of mammalian NCCRP1 proteins

• One intramolecular disulfide bond (Cys158-Cys192) in human NCCRP1

• Proline-rich regions (9% in fish NCCRP1)

• Two glycosylation sites and numerous potential phosphorylation sites (serine, threonine, tyrosine constitute approximately 18% of amino acids)

Understanding these structural features is critical for selecting appropriate antibodies targeting different domains and for interpreting experimental results.

How can researchers distinguish between NCCRP1 and its paralogous FBXO proteins?

Distinguishing between NCCRP1 and its paralogous FBXO proteins requires careful antibody selection and validation. The main differences between these proteins lie in three indels within the F-box domain region, where NCCRP1 has shorter sequences and lacks the signature pattern CRxVC . When generating or selecting antibodies, targeting these unique regions will enhance specificity. Cross-reactivity testing against recombinant FBXO2, FBXO6, FBXO17, FBXO27, and FBXO44 proteins is recommended to confirm specificity. Additionally, researchers should be aware that in humans, FBXO2, FBXO6, and FBXO44 are contiguous genes on chromosome 1, while FBXO17, FBXO27, and NCCRP1 are located on chromosome 19 .

What are the molecular characteristics of recombinant NCCRP1 protein?

Recombinant human NCCRP1 expressed in E. coli and purified by affinity chromatography exhibits the following characteristics:

These characteristics provide valuable reference points for researchers producing or working with recombinant NCCRP1 and for validating antibody specificity .

How can NCCRP1 function be studied using RNA interference approaches?

RNA interference is a valuable approach for studying NCCRP1 function. Previous studies have demonstrated successful silencing of NCCRP1 expression using antisense oligonucleotides in fish nonspecific cytotoxic cells (NCCs), resulting in decreased membrane NCCRP1 expression and inhibition of NCC cytotoxicity . For mammalian systems, siRNA-mediated knockdown can be employed to investigate NCCRP1's role in cellular processes. When designing siRNA experiments, researchers should: (1) target conserved regions of NCCRP1 mRNA, (2) use multiple siRNA sequences to control for off-target effects, (3) validate knockdown efficiency by qRT-PCR and Western blotting with anti-NCCRP1 antibodies, and (4) include appropriate controls (non-targeting siRNA) to ensure specificity of observed phenotypes.

What experimental evidence supports NCCRP1's role as a component of E3 ubiquitin ligase complexes?

The current understanding of NCCRP1 as a component of E3 ubiquitin ligase complexes is supported by several lines of evidence:

• Sequence homology with FBXO proteins, which are known components of E3 ubiquitin ligase complexes

• Presence of an F-box-associated (FBA) domain, characteristic of proteins involved in ubiquitin-mediated protein degradation

• Intracellular localization consistent with a role in the ubiquitin-proteasome system

• Structural features compatible with protein-protein interactions involved in substrate recognition

Researchers investigating this function should consider co-immunoprecipitation experiments using NCCRP1 antibodies to identify interaction partners, ubiquitination assays to assess E3 ligase activity, and proteasome inhibitor studies to determine the impact on potential substrate proteins .

How can alternative splicing or post-translational modifications of NCCRP1 be investigated?

Investigating alternative splicing and post-translational modifications of NCCRP1 requires complementary approaches:

For alternative splicing:

• RT-PCR with primers spanning potential splice junctions

• Isoform-specific qRT-PCR

• RNA-Seq analysis to identify novel splice variants

• Western blotting with NCCRP1 antibodies to detect protein isoforms of different sizes

For post-translational modifications:

• Phosphorylation can be studied using phospho-specific antibodies or phosphoproteomic approaches

• Glycosylation can be assessed using enzymatic deglycosylation followed by Western blotting

• Mass spectrometry to identify specific modification sites

• 2D gel electrophoresis to separate modified forms of the protein

The multiple potential phosphorylation sites (serine, threonine, tyrosine constituting 18% of amino acids) and two glycosylation sites reported in NCCRP1 make this an important area of investigation .

How can researchers investigate evolutionary aspects of NCCRP1?

NCCRP1 presents an interesting case for evolutionary studies due to its presence across vertebrates and structural differences between fish and mammals. Approaches to investigate evolutionary aspects include:

• Comparative genomic analyses of NCCRP1 orthologs across species

• Phylogenetic studies to determine the evolutionary relationship between NCCRP1 and FBXO proteins

• Analysis of selection pressures on different domains using dN/dS ratios

• Functional studies comparing NCCRP1 from different species using species-specific antibodies

Researchers have identified NCCRP1 orthologs in 35 vertebrate genomes, with fugu (Takifugu rubripes) having two orthologs . This diversity makes NCCRP1 a valuable target for studying protein evolution across vertebrate lineages.

What considerations are important when designing immunohistochemistry experiments with NCCRP1 antibodies?

When designing immunohistochemistry experiments with NCCRP1 antibodies, researchers should consider:

• Fixation methods: Optimize fixation protocols to preserve epitope accessibility while maintaining tissue architecture

• Antigen retrieval: Test different antigen retrieval methods to enhance signal

• Antibody validation: Confirm specificity using positive and negative control tissues based on known expression patterns

• Subcellular localization: Focus on cytoplasmic staining patterns, as NCCRP1 is not a membrane protein

• Species differences: Be aware that expression patterns vary significantly between species

• Tissue-specific expression: In humans, focus on tissues containing squamous epithelium, while in mice, expect more ubiquitous expression

• Controls: Include isotype controls and consider peptide competition assays to validate staining specificity

What are common challenges in working with recombinant NCCRP1 protein?

Researchers working with recombinant NCCRP1 protein may encounter several challenges:

• Protein solubility: NCCRP1 may precipitate during buffer exchange, as observed in detailed characterization studies

• Proper folding: The presence of an intramolecular disulfide bond (Cys158-Cys192) in human NCCRP1 suggests the importance of oxidizing conditions for proper folding

• N-terminal processing: Mass spectrometry analysis indicates potential N-terminal processing, with recombinant NCCRP1 appearing to contain residues 31-275

• Protein stability: Consider adding protease inhibitors during purification and storage to prevent degradation

• Expression system selection: E. coli expression systems have been successful, but eukaryotic systems may be necessary for certain applications requiring post-translational modifications

To address these challenges, researchers should optimize buffer conditions, consider adding stabilizing agents, and carefully monitor protein quality using SDS-PAGE and mass spectrometry.

How can researchers optimize Western blotting protocols for NCCRP1 detection?

Optimizing Western blotting protocols for NCCRP1 detection requires attention to several factors:

• Sample preparation: Use appropriate lysis buffers with protease inhibitors to prevent degradation

• Protein loading: Optimize protein loading (typically 20-50 μg of total protein) based on NCCRP1 expression levels

• Gel percentage: Use 10-12% polyacrylamide gels for optimal resolution of the ~30 kDa NCCRP1 protein

• Transfer conditions: Optimize transfer time and voltage for efficient transfer of NCCRP1 to membranes

• Blocking: Test different blocking agents (BSA vs. milk) to minimize background while preserving epitope accessibility

• Antibody dilution: Titrate primary and secondary antibodies to determine optimal concentrations

• Detection method: Choose chemiluminescence or fluorescence-based detection methods based on required sensitivity

• Controls: Include recombinant NCCRP1 as a positive control and lysates from NCCRP1-knockdown cells as negative controls

What are the key considerations for designing NCCRP1 knockout or knockin animal models?

When designing NCCRP1 knockout or knockin animal models, researchers should consider:

• Genomic organization: In humans, NCCRP1 is located on chromosome 19, with FBXO17 and FBXO27 in proximity

• Potential compensation: Monitor expression of paralogous FBXO genes that may compensate for NCCRP1 deletion

• Tissue-specific effects: Given the variable expression patterns across tissues, assess phenotypes in multiple organ systems

• Species differences: Consider that findings in one species may not translate directly to others due to evolutionary differences

• Conditional approaches: Use conditional knockout strategies to overcome potential developmental effects

• Off-target effects: Carefully design CRISPR/Cas9 guide RNAs to minimize off-target modifications

• Validation: Validate models using NCCRP1 antibodies to confirm protein absence or modification

The relationship between NCCRP1 and CA IX suggests that researchers should pay particular attention to gastric and other epithelial tissues when characterizing NCCRP1 knockout models .